Wockhardt’s Chikalthana plant receives GMP certificate from UK health regulator
02 Dec 2015
Drug firm Wockhardt's plant at Chikalthana, Aurangabad in Maharashtra, has received a good manufacturing practice (GMP) certificate from the UK health regulator, Healthcare Products Regulatory Agency (MHRA).
"The company has undergone recently an inspection at its L1-Chikalthana, Aurangabad manufacturing facility by UK MHRA and has received a communication confirming the closure of the inspection and issuance of an unrestricted GMP certificate", Wockhardt said in a filing with the Bombay Stock Exchange (BSE).
In its October filings with the bourses, Workhardt had said the United Kingdom Medicines and Healthcare Products Regulatory Agency (UKMHRA) had completed inspection of the plant and had made no critical observations about the facility.
Withdrawing the GMP certificate in October 2013, the UK regulator had also initiated recall of five prescription medicines from there.
Shares in Wockhardt rose 1.94 per cent to Rs1,690.60 apiece on the BSE, whose benchmark Sensex index finished up 0.09 per cent.
According to the company, its UK business recorded a growth of 88 per cent during the quarter, while the India business clocked 22 per cent growth, and the US business saw a growth of 2 per cent.
Since 2013, two of the company's manufacturing plants in Waluj and Chikalthana had been under a US FDA import alert after they were found to be not in compliance with good manufacturing practices.
The company's L1 Chikalthana plant produces the Metoprolol XR drug used in the treatment of blood pressure, while the Waluj plant manufactures injectables and solid dosages.
